The CEO's total compensation of approximately $6.7 million is reasonable for a biotech company of Spyre's size and stage, with over 92% of his pay being at-risk through stock options and performance-based bonuses — well above the 50-60% variable pay threshold the policy requires. The 2025 annual bonus paid out at 130% of target, which is tied to clearly defined and fully achieved clinical and corporate milestones including Phase 1 trial initiations and a $310 million capital raise, reflecting genuine pay-for-performance alignment. The company's 3-year stock return of +680% dramatically outperforms the XBI — SPDR S&P Biotech ETF benchmark (which returned +69% over the same period), further confirming that above-target incentive pay is well justified by shareholder outcomes; a clawback policy is in place and prior say-on-pay support was a strong 93%.

KPMG was only appointed in February 2025, so tenure is approximately one year and far below the 25-year threshold; non-audit fees (tax services of $116,025) represent about 11% of audit fees of $1,032,594, well within the 50% limit; although a prior auditor change occurred alongside a restatement related to earnings-per-share calculations, the restatement was attributed to a company-side control deficiency rather than an audit failure by the incoming auditor; KPMG is a Big 4 firm appropriate for a $4B market cap company.